ظاهرة دفن الكتب عند الرواة، وأثرها على الراوي والرواية: دراسة استقرائية تحليلية de réir Alasasmeh , Adel Harb Bashir

Ábhair: Faigh an téacs iomlán

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer de réir Samuel Rosner (15054884)

Ábhair:

Supplementary Tables 1-8 from Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER⁺ Br... de réir Gary N. Schwartz (16005870)

Ábhair:

Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes de réir Benjamin K. Wilke (15055112)

Ábhair:

Supplementary Figure S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes de réir Benjamin K. Wilke (15055112)

Ábhair:

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovari... de réir Stephanie L. Wethington (16354020)

Ábhair:

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma de réir Qingsheng Xu (17078830)

Ábhair:

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carci... de réir John A. Ligon (15024477)

Ábhair:

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma de réir Qingsheng Xu (17078830)

Ábhair:

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... de réir Ibrahim Aldoss (15055961)

Ábhair:

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors de réir Kristoffer Staal Rohrberg (15009138)

Ábhair:

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors de réir Kristoffer Staal Rohrberg (15009138)

Ábhair:

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors de réir Kristoffer Staal Rohrberg (15009138)

Ábhair:

Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... de réir Ibrahim Aldoss (15055961)

Ábhair:

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors de réir Kristoffer Staal Rohrberg (15009138)

Ábhair:

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors de réir Kristoffer Staal Rohrberg (15009138)

Ábhair:

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors de réir Kristoffer Staal Rohrberg (15009138)

Ábhair:

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... de réir Ibrahim Aldoss (15055961)

Ábhair:

Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... de réir Ibrahim Aldoss (15055961)

Ábhair:

Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... de réir Ibrahim Aldoss (15055961)

Ábhair: